The specific aims of this research include comparing in vivo cutaneous pharmacokinetic (PK) measurements by independent techniques such as dermal open flow microperfusion (dOFM), dermal microdialysis (dMD), or spectroscopic tomography; exploring the removal of the topical formulations at different time points and characterizing the resulting PK profiles of the test product and the reference standard; developing data analysis techniques; and identifying appropriate PK endpoints for the evaluation of topical BE. The outcomes of this research are expected to help US Food and Drug Administration (US-FDA) improve the efficiency of current BE approaches for topical generic products with compositional differences relative to the reference standard.
Read more about Optimized Clinical Dermal Open Flow Microperfusion Study Design to Demonstrate Bioequivalence Based on Cutaneous Pharmacokinetics here
For the last decade, JOANNEUM RESEARCH HEALTH has been pioneering the use of our proprietary dermal Open Flow Microperfusion (dOFM™) technology to support the translational development of dermal drug products. By obtaining pharmacokinetics and pharmacodynamics data at or near the sites of action in skin, dOFM™ studies have been able to rapidly derisk/endorse drug development decisions. As we are seeking long-term, synergetic partnerships, we are open to innovative propositions to create a win-win arrangement with potential partners. Please forward your letter of interest (LOI) until December 31, 2022
For further inquiry and LOI submission, please visit our dedicated landingpage: Call for Partnership
Joanneum Research HEALTH and RaDes GmbH are committed to accelerate novel therapeutic options for dermatology patients. Confirming our shared vison at the Skin Forum in Malmö, we would like to announce a collaboration of the formulation expertise of RaDes and the dermal Open Flow Microperfusion (dOFM) PK/PD technique of Joanneum Research HEALTH to support rational development of dermatology drug products.
In addition to pharmacokinetic (PK) profiling, HEALTHs unique and powerful dOFM allows pharmacodynamic (PD) profiling. Biological effects of the drug product can be monitored through determination of biomarkers. This offers our clients further de-risking in their development projects before entering into clinical trials.
Our new publication "Advanced Online Monitoring of In Vitro Human 3D Full-Thickness Skin Equivalents" is online.
Skin equivalents and skin explants are widely used for dermal penetration studies in the pharmacological development of drugs. Environmental parameters, such as the incubation and culture conditions affect cellular responses and thus the relevance of the experimental outcome.
However, available systems such as the Franz diffusion chamber, only measure in the receiving culture medium, rather than assessing the actual conditions for cells in the tissue. We developed a sampling design that combines open flow microperfusion (OFM) sampling technology for continuous concentration measurements directly in the tissue with microfluidic biosensors for online monitoring of culture parameters. We tested our design with real-time measurements of oxygen, glucose, lactate, and pH in full-thickness skin equivalent and skin explants.
Furthermore, we compared dermal penetration for acyclovir, lidocaine, and diclofenac in skin equivalents and skin explants. We observed differences in oxygen, glucose, and drug concentrations in skin equivalents compared to the respective culture medium and to skin explants.
Biocrates Targeted Metabolomics Assays have become an international standard, so this certification is another important milestone in intensifying the cooperation between biocrates and JOANNEUM RESEARCH in the field of metabolomics. JOANNEUM RESEARCH now also offers analyses with certified high analysis quality based on the Biocrates Metabolomics Assays. Absolute quantification and thus comparability across studies in combination with the determination of up to 500 metabolites per sample characterize the implemented targeted metabolomics methods.
Dr. Joanna Hummer and Dr. Florie Le Prieult share insights into cOFM's use and utility in the broader neuroscience field and specifically for the development of drugs for neurodegenerative diseases.
Presentation with Speaker Notes
Discover selected analytical methods for diabetes and obesity research by joining our latest webinar. Our speakers address a range of interesting topics, including the quantification of peptides that regulate metabolism and the use of stable isotope tracers in clinical trials. View the on-demand version for free and download the presentation slides with some additional comments from our experts Dr. Thomas Pieber, Dr. Reingard Raml and Dr. Christoph Magnes.
Presentation Slides with Speaker Notes
In the latest issue of the Journal MABS, Florie Le Prieult and colleagues from AbbVie Germany published latest results they observed after measuring concentrations of a monoclonal anitbody - trastuzumab - in the interstitial brain fluid (ISF) of awake and freely moving mice. The only currently available methods for extracting ISF, are Microdialysis (MD) and cerebral open flow microperfusion (cOFM).
For the first time, both methods were compared at a technical and performance level for the collection of large molecules in rodents. They found 10-fold higher absolute concentrations in cOFM samples compared to MD. In vivo recovery revealed an increased extraction of trastuzumab at low flow rates and a 6-fold higher absolute concentration at steady state than initially calculated with the in vitro recovery.
The authors conclude that the “standardization of these complex methods makes the unraveling of ISF concentrations attainable for various diseases and modalities, starting in this study with mAbs, but extending further in the future to RNA therapeutics, antibody-drug conjugates, and even cell therapies.”
We are pleased to announce that JOANNEUM Research HEALTH has successfully renewed the GLP certification for its analytical laboratory, strengthening its positioning as a competent and professional partner for the pharmaceutical industry. Our analytical laboratory develops analytical methods in the research areas of bioanalytics and metabolomics and combines scientific competence with GLP/GCP standards for both complex research projects and drug development programs. We focus on the high quality of analytical results that are both traceable and tailored to the needs of our customers.
Download: GLP Certificate
We are pleased to announce that we have prepared some useful content from our Webinar "Informed decisions in dermal drug development with dOFM". Please find below a collection of valuable insights, a comprehensive Q&A Catalogue and easy access to all relevant resources. Browse through a collection of questions raised by our listeners during the live webinar to see which topics are particularly relevant for our audience. Take a more detailed look at the slides and download the presentation including some additional notes from our dOFM experts.
In a cooperative contract research project, HEALTH and Med Uni Graz have tested a new insulin in a clinical phase 1 study on behalf of Arecor. The study, in which HEALTH was responsible for insulin analysis, statistical evaluation, clinical data management, and quality management, showed that the new insulin enters the bloodstream more quickly and thus also acts faster. As a result, blood glucose control in type 1 diabetics is optimized and dangerous hyper- and hypoglycemia can be avoided. The study results are now published in the top-ranking Journal Diabetes Care.
This new type of fast-acting insulin is an important step in the development of an artificial pancreas. HEALTH is proud to support our clients with new developments to further improve the lives of people with diabetes.
Dr Thomas Birngruber and Dr Frank Sinner will present valuable insights on improved formulation screening and local dermal PK and PD using dOFM sampling. This webinar will give you a concise overview of dOFM capabilities and introduce possible setups for preclinical and clinical studies. We will present several case studies for drug development, biomarker discovery and bioequivalence assessment. More information
Our experts will answer all your questions personally, such as:
HEALTH – Institute for Biomedical Research and Technologies
Neue Stiftingtalstrasse 2/Entrance A/Third Floor
Phone: +43 316 876-4000
Fax: +43 316 8769-4000